1048 – Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates
Background Rapid maturation of metabolic/elimination pathways during the first month of life complicates using pediatric fixed-dose dispersible formulations in neonates. We previously reported that once daily administration of abacavir/lamivudine dispersible tablets (ABC/3TC-DT) to neonates gave high exposure during the first week of life. Administration of 5 mg dolutegravir (DTG) every 48 hours (q48) for the…